A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs KD 025 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kadmon Corporation
- 03 Aug 2017 According to a Kadmon media release, additional study results submitted for presentation at upcoming scientific conferences.
- 25 Jul 2017 Supplemental interim results published in a Kadmon Pharmaceuticals media release.
- 11 Jul 2017 According to a Kadmon media release, interim results were webcast and presented at Kadmons Research and Development (R&D) Day in New York 2017.